Supplementary Figures S1 - S11 from NOTCH Decoys That Selectively Block DLL/NOTCH or JAG/NOTCH Disrupt Angiogenesis by Unique Mechanisms to Inhibit Tumor Growth

Figure S1 shows that N11-13 decoy blocks activation of Notch1 by DLL1 but not JAG2 whereas N110-24 decoy blocks activation of Notch1 by JAG2 but not DLL1. Figure S2 shows that purified N11-13 decoy preferentially inhibited DLL4-mediated Notch1 activation, while purified N11-24 decoy inhibited both DLL4 and JAG1-mediated Notch1 activation. Figure S3 shows using co-immunoprecipitation of N1 decoys and soluble versions of DLL4 and JAG1 lacking transmembrane domains that similar ligand specificity of the decoys was observed as when using membrane bound DLL4 or JAG1. Figure S4 shows serum levels of Notch1 decoys in P5 neonatal mice. Figure S5 shows N1 decoys that block JAG disrupted vascular smooth muscle cell association in the actively remodeling neonatal retinal vasculature, but not the mature retinal vasculature. Figure S6 shows that N11-13, N110-24, and N11-24 decoys block soft agar growth of Mm5MT-FGF4 tumor cells but do not affect growth of KP1-VEGF, LLC or B16-F10 tumor lines. Figure S7 shows N1 decoys detected in mouse serum after adenovirus infection and quantification of these levels using ELISA. Figure S8 shows that JAG- inhibiting decoys disrupt vascular smooth muscle coverage in tumors. Figure S9 shows that N1 decoys expressed in mice cause a modest increase of intestinal goblet cells but no significant change in murine weight. Figure S10 shows N1 decoys had no effect on serum markers of liver damage. Figure S11 shows N1 decoys did not affect liver and kidney histopathology.